Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Mechanism of Action
Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue.
Dosage Overview
Dose Range
2 mg
Route
subcutaneous
Frequency
1x daily
Cycle Length
12–52 weeks
Reconstitution
Typical Dosage (Research)
FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules.
Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening.
Considerations for Men & Women
Women: FDA-approved for HIV-associated lipodystrophy in both sexes, but clinical trials included predominantly male participants. Women may experience more injection site reactions. Contraindicated during pregnancy — tesamorelin may affect fetal development. Not recommended during breastfeeding.
Men: Primary study population for lipodystrophy indication. May see improvements in visceral adipose tissue and trunk fat. GH response may be influenced by concurrent testosterone levels.
Individual responses vary. These notes reflect general trends from research literature and are not medical advice.
Quick Calculator
Quick Calculator
Concentration: 1,000 mcg/ml
Volume to inject: 2.00 ml
Syringe units (U-100): 200.0 units
Pre-filled with Tesamorelin defaults. Adjust values as needed.
Side Effects & Risks
Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose.
Contraindicated in patients with active malignancy, hypersensitivity to GHRH, or during pregnancy. May affect glucose metabolism. Requires monitoring of IGF-1 levels.
Where to Buy Tesamorelin
All Vendor Details →US-based vendor with third-party HPLC testing and published COAs. One of the few reputable sources we've verified for research-grade peptides.
Some links on this page are affiliate links — we may earn a commission at no extra cost to you. Learn more.
Finnrick grades are based on independent HPLC lab testing. Learn more · Finnrick is a commercial service — ratings are third-party, not independent.
Who Uses Tesamorelin
HIV patients with lipodystrophy (approved use), individuals seeking fat loss, those interested in GH-related benefits without direct GH administration.
Similar Peptides
View All Alternatives →IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Human Growth Hormone (somatropin) is a 191-amino acid protein identical to naturally produced GH. FDA-approved for growth hormone deficiency, Turner syndrome, and other conditions. Widely used off-label for anti-aging and performance.
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a mitochondrial-derived peptide that plays a key role in metabolic regulation and has emerged as a significant longevity research target.